This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.


Explore ELIQUIS® for stroke prevention in your patients with NVAF

ELIQUIS – an oral, direct factor Xa inhibitor – is indicated for:

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II).1

ARISTOTLE Clinical Trial

ELIQUIS demonstrated a superior risk reduction in stroke / systemic embolism with significantly less major bleeding vs. warfarin in patients with NVAF2

AUGUSTUS Clinical Trial

ELIQUIS has been compared with VKA in patients with NVAF after a recent ACS and / or PCI who received concomitant antiplatelet therapy3

Treatment Guidelines in NVAF

ELIQUIS is recommended by NICE as a treatment option for preventing stroke and systemic embolism in patients with NVAF, with one or more risk factors4*

Real-World Data

ELIQUIS offered superior reductions in the rates of stroke / systemic embolism AND major bleeding vs. warfarin in ARISTOTLE, these results are complemented by real-world evidence2,5

FOOTNOTES

* ELIQUIS is recommended as a treatment option within its marketing authorisation, that is, in patients with NVAF and one or more risk factors, such as prior stroke or TIA, age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II).1,4

ACS = Acute Coronary Syndrome   NICE = National Institute for Health and Care Excellence   NVAF = Non-Valvular Atrial Fibrillation   
NYHA = New York Heart Association   PCI = Percutaneous Coronary Intervention   PE = Pulmonary Embolism
TIA = Transient Ischaemic Attack   VKA = Vitamin K Antagonist

REFERENCES

  1. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at www.medicines.org.uk.
  2. Granger CB et al. N Engl J Med 2011; 365: 981–992.
  3. Lopes RD et al. N Engl J Med 2019; 365: 883–891.
  4. NICE Guideline 196. Atrial fibrillation: diagnosis and management. April 2021.
  5. Lip GH et al. Stroke. 2018; 49: 2933–2944.